Screener
Stoke Therapeutics, Inc. STOK Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
FAQ
- What is Stoke Therapeutics, Inc.'s debt-to-equity?
- Stoke Therapeutics, Inc. (STOK) reported debt-to-equity of 0× in Q1 2026.
- How has Stoke Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Stoke Therapeutics, Inc.'s debt-to-equity decreased by 48.8% year-over-year, from 0× to 0×.
- What is the long-term trend for Stoke Therapeutics, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s debt-to-equity has grown at a 24.2% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Stoke Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude